Table of Contents
ISRN Cardiology
Volume 2013 (2013), Article ID 903454, 11 pages
http://dx.doi.org/10.1155/2013/903454
Review Article

Human Immunodeficiency Virus and Pulmonary Arterial Hypertension

Department of Internal Medicine, Saint Joseph Hospital, 2900 North Lake Shore, Chicago, LL 60657, USA

Received 27 June 2013; Accepted 23 July 2013

Academic Editors: B. Strasberg and A. Szekely

Copyright © 2013 Aibek E. Mirrakhimov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Simonneau, I. M. Robbins, M. Beghetti et al., “Updated clinical classification of pulmonary hypertension,” Journal of the American College of Cardiology, vol. 54, no. 1, pp. S43–S54, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Oswald-Mammosser, E. Weitzenblum, E. Quoix et al., “Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure,” Chest, vol. 107, no. 5, pp. 1193–1198, 1995. View at Google Scholar · View at Scopus
  3. I. M. Lang and R. Benza, “Pulmonary hypertension: chapters of innovation and tribulation,” European Heart Journal, vol. 33, no. 8, pp. 961–968, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. E. Mirrakhimov and N. S. Hill, “Primary antiphospholipid syndrome and pulmonary hypertension,” Current Pharmaceutical Design. In press.
  5. Centers for Disease Control (CDC), “Pneumocystis pneumonia—Los Angeles,” CDC—Morbidity and Mortality Weekly Report, vol. 30, pp. 250–252, 1981. View at Google Scholar
  6. Centers for Disease Control (CDC), “Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men–New York City and California,” CDC—Morbidity and Mortality Weekly Report, vol. 30, pp. 305–308, 1981. View at Google Scholar
  7. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf.
  8. D. C. Douek, M. Roederer, and R. A. Koup, “Emerging concepts in the immunopathogenesis of AIDS,” Annual Review of Medicine, vol. 60, pp. 471–484, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. L. Jones, D. L. Hanson, M. S. Dworkin et al., “Surveillance for AIDS-defining opportunistic illnesses, 1992–1997,” CDC—Morbidity and Mortality Weekly Report, vol. 48, no. 2, pp. 1–22, 1999. View at Google Scholar · View at Scopus
  10. S. Franceschi, M. Lise, G. M. Clifford et al., “Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study,” British Journal of Cancer, vol. 103, no. 3, pp. 416–422, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Boccara, S. Lang, C. Meuleman et al., “HIV and coronary heart disease: time for a better understanding,” Journal of the American College of Cardiology, vol. 61, pp. 511–523, 2013. View at Publisher · View at Google Scholar
  12. C. M. Wyatt, “The kidney in HIV infection: beyond HIV-associated nephropathy,” Topics in Antiviral Medicine, vol. 20, pp. 106–110, 2012. View at Google Scholar
  13. K. K. Kim and S. M. Factor, “Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome,” Human Pathology, vol. 18, no. 12, pp. 1293–1296, 1987. View at Google Scholar · View at Scopus
  14. R. Speich, R. Jenni, M. Opravil, M. Pfab, and E. W. Russi, “Primary pulmonary hypertension in HIV infection,” Chest, vol. 100, no. 5, pp. 1268–1271, 1991. View at Google Scholar · View at Scopus
  15. K. Crothers, L. Huang, J. L. Goulet et al., “HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 3, pp. 388–395, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Sitbon, C. Lascoux-Combe, J.-F. Delfraissy et al., “Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 1, pp. 108–113, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. N. J. Mehta, I. A. Khan, R. N. Mehta, and D. A. Sepkowitz, “HIV-related pulmonary hypertension: analytic review of 131 cases,” Chest, vol. 118, no. 4, pp. 1133–1141, 2000. View at Google Scholar · View at Scopus
  18. M. Humbert, O. Sitbon, A. Chaouat et al., “Pulmonary arterial hypertension in France: results from a national registry,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 9, pp. 1023–1030, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Quezada, L. Martin-Carbonero, V. Soriano et al., “Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up,” AIDS, vol. 26, pp. 1387–1392, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Nunes, M. Humbert, O. Sitbon et al., “Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 10, pp. 1433–1439, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Y. Hsue, S. G. Deeks, H. H. Farah et al., “Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension,” AIDS, vol. 22, no. 7, pp. 825–833, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Degano, M. Guillaume, L. Savale et al., “HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era,” AIDS, vol. 24, no. 1, pp. 67–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Reinsch, C. Buhr, P. Krings et al., “Effect of gender and highly active antiretroviral therapy on HIV-related pulmonary arterial hypertension: results of the HIV-HEART Study,” HIV Medicine, vol. 9, no. 7, pp. 550–556, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Isasti, I. Pérez, T. Moreno, F. Cabrera, R. Palacios, and J. Santos, “Echocardiographic abnormalities and associated factors in a cohort of asymptomatic HIV-infected patients,” AIDS Research and Human Retroviruses, vol. 29, pp. 20–24, 2013. View at Publisher · View at Google Scholar
  25. G. Isasti, T. Moreno, I. Pérez, F. Cabrera, R. Palacios, and J. Santos, “High prevalence of pulmonary arterial hypertension in a cohort of asymptomatic HIV-infected patients,” AIDS Research and Human Retroviruses, vol. 29, pp. 231–234, 2013. View at Google Scholar
  26. A. Niakara, Y. J. Drabo, Y. Kambire, L. V. A. Nebie, N. J. P. Kabore, and F. Simon, “Cardiovascular diseases and HIV infection: a study of 79 cases in the national hospital of Ouagadougou (Burkina Faso),” Bulletin de la Societe de Pathologie Exotique, vol. 95, no. 1, pp. 23–26, 2002. View at Google Scholar · View at Scopus
  27. A. Morris, M. R. Gingo, M. P. George et al., “Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era,” AIDS, vol. 26, no. 6, pp. 731–740, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. V. N. Selby, R. Scherzer, C. F. Barnett et al., “Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients,” AIDS, vol. 26, pp. 1967–1969, 2012. View at Publisher · View at Google Scholar
  29. S. C. Mathai and P. M. Hassoun, “Pulmonary arterial hypertension in connective tissue diseases,” Heart Failure Clinics, vol. 8, pp. 413–425, 2012. View at Publisher · View at Google Scholar
  30. G. S. Ahearn, V. F. Tapson, A. Rebeiz, and J. C. Greenfield Jr., “Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease,” Chest, vol. 122, no. 2, pp. 524–527, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. M. R. Fisher, P. R. Forfia, E. Chamera et al., “Accuracy of doppler echocardiography in the hemodynamic assessment of pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 7, pp. 615–621, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. X.-G. Sun, J. E. Hansen, R. J. Oudiz, and K. Wasserman, “Pulmonary function in primary pulmonary hypertension,” Journal of the American College of Cardiology, vol. 41, no. 6, pp. 1028–1035, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. F. J. Meyer, R. Ewert, M. M. Hoeper et al., “Peripheral airway obstruction in primary pulmonary hypertension,” Thorax, vol. 57, no. 6, pp. 473–476, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. A. J. Fishman, K. M. Moser, and P. F. Fedullo, “Perfusion lung scans vs pulmonary angiography in evaluation of suspected pulmonary hypertension,” Chest, vol. 84, no. 6, pp. 679–683, 1983. View at Google Scholar · View at Scopus
  35. K. L. Ryan, P. F. Fedullo, G. B. Davis, T. E. Vasquez, and K. M. Moser, “Perfusion scan findings understate the severity of angiographic and hemodynamic compromise in chronic thromboembolic pulmonary hypertension,” Chest, vol. 93, no. 6, pp. 1180–1185, 1988. View at Google Scholar · View at Scopus
  36. A. A. Vazquez, J. F. Aduen, P. Aduen, M. G. Heckman, and C. D. Burger, “Should all patients with pulmonary hypertension undergo HIV serologic testing?” Southern Medical Journal, vol. 104, no. 8, pp. 589–592, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. A. C. Miller and M. T. Gladwin, “Pulmonary complications of sickle cell disease,” American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 11, pp. 1154–1165, 2012. View at Publisher · View at Google Scholar
  38. M. Opravil, M. Pechère, R. Speich et al., “HIV-associated primary pulmonary hypertension: a case control study,” American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 3, pp. 990–995, 1997. View at Google Scholar · View at Scopus
  39. P. Petitpretz, F. Brenot, R. Azarian et al., “Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension,” Circulation, vol. 89, no. 6, pp. 2722–2727, 1994. View at Google Scholar · View at Scopus
  40. M. Humbert, G. Monti, M. Fartoukh et al., “Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients,” European Respiratory Journal, vol. 11, no. 3, pp. 554–559, 1998. View at Google Scholar · View at Scopus
  41. G. D. Kanmogne, C. Primeaux, and P. Grammas, “Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins,” Biochemical and Biophysical Research Communications, vol. 333, no. 4, pp. 1107–1115, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. H. W. Kestler III, D. J. Ringler, K. Mori et al., “Importance of the nef gene for maintenance of high virus loads and for development of AIDS,” Cell, vol. 65, no. 4, pp. 651–662, 1991. View at Publisher · View at Google Scholar · View at Scopus
  43. J. C. Marecki, C. D. Cool, J. E. Parr et al., “HIV-1 nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 4, pp. 437–445, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. C. O. James, M.-B. Huang, M. Khan, M. Garcia-Barrio, M. D. Powell, and V. C. Bond, “Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors,” Journal of Virology, vol. 78, no. 6, pp. 3099–3109, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. F. M. Hofman, A. D. Wright, M. M. Dohadwala, F. Wong-Staal, and S. M. Walker, “Exogenous tat protein activates human endothelial cells,” Blood, vol. 82, no. 9, pp. 2774–2780, 1993. View at Google Scholar · View at Scopus
  46. R. L. Caldwell, R. Gadipatti, K. B. Lane, and V. L. Shepherd, “HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells,” Journal of Leukocyte Biology, vol. 79, no. 1, pp. 192–201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Rabinovitch, “Molecular pathogenesis of pulmonary arterial hypertension,” The Journal of Clinical Investigation, vol. 122, pp. 4306–4313, 2012. View at Publisher · View at Google Scholar
  48. J. Rucker and R. W. Doms, “Chemokine receptors as HIV coreceptors: implications and interactions,” AIDS Research and Human Retroviruses, vol. 14, supplement 3, pp. S241–S246, 1998. View at Google Scholar · View at Scopus
  49. H. Ehrenreich, P. Rieckmann, F. Sinowatz et al., “Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120,” Journal of Immunology, vol. 150, no. 10, pp. 4601–4609, 1993. View at Google Scholar · View at Scopus
  50. J. Mermis, H. Gu, B. Xue et al., “Hypoxia-inducible factor-1 α/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling,” Respiratory Research, vol. 12, article 103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. A. S. Fauci, G. Pantaleo, S. Stanley, and D. Weissman, “Immunopathogenic mechanisms of HIV infection,” Annals of Internal Medicine, vol. 124, no. 7, pp. 654–663, 1996. View at Google Scholar · View at Scopus
  52. K. E. Mondy, J. Gottdiener, E. T. Overton et al., “High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy,” Clinical Infectious Diseases, vol. 52, pp. 378–386, 2011. View at Publisher · View at Google Scholar
  53. G. Ascherl, C. Hohenadl, O. Schatz et al., “Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy,” Blood, vol. 93, no. 12, pp. 4232–4241, 1999. View at Google Scholar · View at Scopus
  54. E. J. Ariza-Heredia and R. R. Razonable, “Human herpes virus 8 in solid organ transplantation,” Transplantation, vol. 92, no. 8, pp. 837–844, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. C. D. Cool, P. R. Rai, M. E. Yeager et al., “Expression of human herpesvirus 8 in primary pulmonary hypertension,” New England Journal of Medicine, vol. 349, no. 12, pp. 1113–1122, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. J. N. Martin, D. E. Ganem, D. H. Osmond, K. A. Page-Shafer, D. Macrae, and D. H. Kedes, “Sexual transmission and the natural history of human herpesvirus 8 infection,” New England Journal of Medicine, vol. 338, no. 14, pp. 948–954, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. Centers for Disease Control and Prevention (CDC), “HIV infections attributed to male-to-male sexual contact—metropolitan statistical areas, United States and Puerto Rico, 2010,” CDC—Morbidity and Mortality Weekly Report, vol. 61, pp. 962–966, 2012. View at Google Scholar
  58. D. Montani, A.-G. Marcelin, O. Sitbon, V. Calvez, G. Simonneau, and M. Humbert, “Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France,” AIDS, vol. 19, no. 11, pp. 1239–1240, 2005. View at Google Scholar · View at Scopus
  59. E. Nicastri, C. D. Vizza, F. Carletti et al., “Human herpesvirus 8 and pulmonary hypertension,” Emerging Infectious Diseases, vol. 11, no. 9, pp. 1480–1482, 2005. View at Google Scholar · View at Scopus
  60. C. D. Cool, N. F. Voelkel, and T. Bull, “Viral infection and pulmonary hypertension: is there an association?” Expert Review of Respiratory Medicine, vol. 5, no. 2, pp. 207–216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. S. D. Swain, S. Han, A. Harmsen, K. Shampeny, and A. G. Harmsen, “Pulmonary hypertension can be a sequela of prior pneumocystis pneumonia,” American Journal of Pathology, vol. 171, no. 3, pp. 790–799, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. N. K. Dhillon, F. Li, B. Xue et al., “Effect of cocaine on human immunodeficiency virus-mediated pulmonary endothelial and smooth muscle dysfunction,” American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 1, pp. 40–52, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. L. Spikes, P. Dalvi, O. Tawfik et al., “Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine,” American Journal of Respiratory and Critical Care Medicine, vol. 185, pp. 1235–1243, 2012. View at Publisher · View at Google Scholar
  64. M. P. George, H. C. Champion, M. T. Gladwin, K. A. Norris, and A. Morris, “Injection drug use as a, “second hit” in the pathogenesis of HIV-associated pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 185, pp. 1144–1146, 2012. View at Publisher · View at Google Scholar
  65. M. Bibas, G. Biava, and A. Antinori, “HIV-associated venous thromboembolism,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 3, article e2011030, 2011. View at Google Scholar
  66. V. Y. Hebert, B. L. Crenshaw, R. L. Romanoff, V. P. Ekshyyan, and T. R. Dugas, “Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation,” Cardiovascular Toxicology, vol. 4, no. 2, pp. 117–131, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. J. H. Morse, R. J. Barst, S. Itescu et al., “Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles,” American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 4, pp. 1299–1301, 1996. View at Google Scholar · View at Scopus
  68. V. V. McLaughlin, S. L. Archer, D. B. Badesch et al., “ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association,” Journal of the American College of Cardiology, vol. 53, no. 17, pp. 1573–1619, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. L. Fuso, F. Baldi, and A. Di Perna, “Therapeutic strategies in pulmonary hypertension,” Frontiers in Pharmacology, vol. 2, article 21, 2011. View at Google Scholar
  70. L. J. Rubin, “Introduction. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines,” Chest, vol. 126, pp. 7S–10S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. O. Schumacher, A. Zdebik, M. Huonker, and W. Kreisel, “Sildenafil in HIV-related pulmonary hypertensin,” AIDS, vol. 15, no. 13, pp. 1747–1748, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Carlsen, K. Kjeldsen, and J. Gerstoft, “Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension,” AIDS, vol. 16, no. 11, pp. 1568–1569, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. A. R. Wong, A. H. G. Rasool, N. Z. Abidin, A. R. Noor, and B. S. Quah, “Sildenafil as treatment for Human Immunodeficiency Virus-related pulmonary hypertension in a child,” Journal of Paediatrics and Child Health, vol. 42, no. 3, pp. 147–148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. C. Merry, M. G. Barry, M. Ryan et al., “Interaction of sildenafil and indinavir when co-administered to HIV-positive patients,” AIDS, vol. 13, no. 15, pp. F101–F107, 1999. View at Google Scholar · View at Scopus
  75. P. Chinello, S. Cicalini, S. Pichini, R. Pacifici, M. Tempestilli, and N. Petrosillo, “Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors,” Current HIV Research, vol. 10, no. 2, pp. 162–164, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. O. Sitbon, V. Gressin, R. Speich et al., “Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 11, pp. 1212–1217, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Degano, A. Yaïci, J. Le Pavec et al., “Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension,” European Respiratory Journal, vol. 33, no. 1, pp. 92–98, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. R. V. Aguilar and H. W. Farber, “Epoprostenol (Prostacyclin) therapy in HIV-associated pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 5, pp. 1846–1850, 2000. View at Google Scholar · View at Scopus
  79. L. Cea-Calvo, P. Escribano Subías, R. Tello de Menesses et al., “Treatment of HIV-associated pulmonary hypertension with treprostinil,” Revista Española de Cardiología, vol. 56, pp. 421–425, 2003. View at Google Scholar
  80. H. A. Ghofrani, G. Friese, T. Discher et al., “Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension,” European Respiratory Journal, vol. 23, no. 2, pp. 321–326, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. C. Tcherakian, E. Rivaud, D. Zucman, A.-C. Metivier, and L.-J. Couderc, “Curing HIV-associated pulmonary arterial hypertension,” European Respiratory Journal, vol. 39, no. 4, pp. 1045–1046, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. J. A. C. Sterne, M. A. Hernán, B. Ledergerber et al., “Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study,” The Lancet, vol. 366, no. 9483, pp. 378–384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. J.-P. Zuber, A. Calmy, J. M. Evison et al., “Pulmonary arterial hypertension related to HIV infection: Improved hemodynamics and survival associated with antiretroviral therapy,” Clinical Infectious Diseases, vol. 38, no. 8, pp. 1178–1185, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. June 2013, http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
  85. G. Gary-Bobo, A. Houssaini, V. Amsellem et al., “Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats,” Circulation, vol. 122, no. 19, pp. 1937–1947, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. A. E. Lammers, S. G. Haworth, and G.-P. Diller, “Atrial septostomy in patients with pulmonary hypertension: should it be recommended?” Expert Review of Respiratory Medicine, vol. 5, no. 3, pp. 363–376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. J. J. Esch, P. B. Shah, B. A. Cockrill et al., “Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience,” The Journal of Heart and Lung Transplantation, vol. 32, no. 4, pp. 381–387, 2013. View at Publisher · View at Google Scholar
  88. A. M. Keogh, E. Mayer, R. L. Benza et al., “Interventional and surgical modalities of treatment in pulmonary hypertension,” Journal of the American College of Cardiology, vol. 54, no. 1, pp. S67–S77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. P. A. Grossi, “Update in HIV infection in organ transplantation,” Current Opinion in Organ Transplantation, vol. 17, pp. 586–593, 2012. View at Publisher · View at Google Scholar